Skip to main content

Anika Therapeutics Value Stock - Dividend - Research Selection

Anika therapeutics

ISIN: US0352551081 , WKN: 889120

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company\'s dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. has a strategic collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst to develop a therapy for rheumatoid arthritis. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


12 Health Care Stocks Moving In Monday's Pre-Market Session

2026-03-23

Top 2 Health Care Stocks That May Crash This Quarter

2026-03-04
2 stocks in healthcare sector flashing warning to investors who value momentum. RSI is an indicator that compares stock strength on up and down days.

Anika Therapeutics, Inc. (ANIK) Presents at 2026 CG Musculoskeletal Conference - Slideshow

2026-03-02

Anika Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation

2026-02-27

ANIKA THERAPEUTICS INC (NASDAQ:ANIK) Delivers Decisive Q4 2025 Earnings Beat, Sparking Share Rally

2026-02-26
Anika Therapeutics' Q4 2025 earnings crushed estimates, sparking a major stock rally. Revenue and EPS beat forecasts, driven by 22% growth in its Commercial Channel.

Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript

2026-02-26

Anika Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.

2026-02-26

Insights into Anika Therapeutics Q4 Earnings

2026-02-26

Anika Therapeutics Sees FY2026 Sales $114.000M-$122.500M vs $116.351M Est

2026-02-26
Fiscal 2026 GuidanceAnika is providing the following 2026 guidance:Total Company Revenue between $114 and $122.5 million, up 1% to 9% year over yearCommercial Channel, $53 to $58 million, maintaining up 10% to 20% year

Anika Therapeutics Q4 Adj. EPS $0.31 Beats $(0.21) Estimate, Sales $30.615M Beat $28.875M Estimate

2026-02-26
Anika Therapeutics (NASDAQ:ANIK) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $(0.21) by 244.19 percent. This is a 1133.33 percent increase over losses of $(0.03) per share